Aquestive Therapeutics (AQST) Shares Outstanding (Weighted Average) (2017 - 2026)

Aquestive Therapeutics' Shares Outstanding (Weighted Average) history runs 10 years deep, the most recent figure standing at $122.6 million for Q1 2026.

• In Q1 2026, Shares Outstanding (Weighted Average) rose 28.39% year-over-year to $122.6 million; the TTM figure through Mar 2026 stood at $122.6 million (up 28.39% YoY), while the FY2025 annual figure was $106.9 million, up 23.29% from the prior year.
• Shares Outstanding (Weighted Average) was $122.6 million for Q1 2026 at Aquestive Therapeutics, up from $106.9 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $122.6 million in Q1 2026 to a low of $41.5 million in Q1 2022.
• Historically, Shares Outstanding (Weighted Average) has averaged $75.7 million across 5 years, with a median of $73.6 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Shares Outstanding (Weighted Average) soared 58.52% in 2024, then grew 7.16% in 2025.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $48.7 million in 2022, then advanced by 25.69% to $61.3 million in 2023, then soared by 41.58% to $86.7 million in 2024, then rose by 23.29% to $106.9 million in 2025, then grew by 14.67% to $122.6 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $122.6 million (Q1 2026), $106.9 million (Q4 2025), and $101.9 million (Q3 2025), per Business Quant data.